Completed
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
NCT03290079
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Neuroendocrine, +9 more
- Locations
-
- H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States